Genprex Secures Israeli Patent for Reqorsa Gene Therapy in Combination with PD-1 Antibodies

summarizeSummary

Genprex announced it has been granted a patent in Israel for its Reqorsa Gene Therapy, covering its use in combination with PD-1 antibodies for cancer treatment, expanding its global intellectual property portfolio.

check_boxKey Events

• Israeli Patent Granted

  The Israel Patent Office has granted Genprex a patent covering the use of Reqorsa® Gene Therapy in combination with PD-1 antibodies for the treatment of cancer.

• Global IP Expansion

  This patent expands Genprex's existing intellectual property for Reqorsa, which already includes patents in major markets such as the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore, and Europe.

• Strategic Context Amidst Challenges

  This positive development in intellectual property comes as Genprex navigates proposals for a reverse stock split to maintain its Nasdaq listing, providing a boost to its R&D narrative.

auto_awesomeAnalysis

This patent grant in Israel strengthens Genprex's intellectual property for its lead gene therapy candidate, Reqorsa, particularly for its use in combination with PD-1 antibodies in cancer treatment. For a micro-cap company like Genprex, which is currently facing challenges related to Nasdaq listing requirements and proposing a significant reverse stock split, any positive development in its core R&D and IP portfolio is crucial. This news, following recent positive preclinical data and a research agreement, provides a much-needed positive signal, demonstrating continued scientific progress and potential long-term value, despite the immediate financial pressures.